1,308 results on '"Moliterno, David J."'
Search Results
2. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
3. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
4. Acute Coronary Syndromes Among Patients with Prior Coronary Artery Bypass Surgery
5. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
6. Coronary Physiology Assessment
7. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
8. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry
9. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)
10. Glycoprotein IIb/IIIa Antagonists
11. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
12. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
13. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites
14. LB-9 | Repeated Coronary Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
15. JACC Journals’ Pathway Forward With AI Tools
16. Immediate vs Delayed Coronary Angiography for Out-of-Hospital Cardiac Arrest
17. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry
18. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry
19. The evolution of medical resident training and healthcare delivery: Good riddance to the “July effect”
20. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
21. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry
22. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
23. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry
24. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
25. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
26. Toward a More Interactive Central Illustration
27. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
28. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
29. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
30. Rescue Coronary Intervention for Failed Thrombolysis
31. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update
32. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)
33. Hybrid coronary revascularization: Time for a new comparator?
34. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
35. Revascularisation for patients with stable coronary artery disease
36. Vasopressors, Vasodilators, and Antithromboticsin The Catheterization Laboratory
37. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy
38. Antiplatelet Agents
39. Unstable Angina Trials : PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV
40. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)
41. Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions
42. Unstable Angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS
43. Meta-Analysis of Long-Term Outcomes for Drug-Eluting Stents Versus Bare-Metal Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction
44. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD
45. JACC: Cardiovascular Interventions Top Reviewers 2021
46. Evolving our learning and application of knowledge to practice—The ongoing challenges of time and cost in interventional cardiology
47. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension
48. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
49. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials
50. The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.